Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19.
作者信息
Bozkurt Biykem, Kovacs Richard, Harrington Bob
出版信息
J Card Fail. 2020 May;26(5):370. doi: 10.1016/j.cardfail.2020.04.013.
Abstract
摘要
相似文献
1
Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19.
J Card Fail. 2020 May;26(5):370. doi: 10.1016/j.cardfail.2020.04.013.
2
Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence.
Can J Cardiol. 2020 Aug;36(8):1180-1182. doi: 10.1016/j.cjca.2020.05.033. Epub 2020 Jun 2.
3
Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week.
J Am Coll Cardiol. 2020 Jun 23;75(24):3085-3095. doi: 10.1016/j.jacc.2020.04.028. Epub 2020 Apr 16.
4
Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?
Eur J Pharmacol. 2020 Sep 15;883:173373. doi: 10.1016/j.ejphar.2020.173373. Epub 2020 Jul 15.
5
COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure.
mBio. 2020 May 22;11(3):e00946-20. doi: 10.1128/mBio.00946-20.
6
Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities.
Pharmacol Ther. 2020 Nov;215:107628. doi: 10.1016/j.pharmthera.2020.107628. Epub 2020 Jul 9.
7
Cardiovascular disease and the impact of COVID-19.
J Card Surg. 2020 Aug;35(8):2113. doi: 10.1111/jocs.14682. Epub 2020 Jun 16.
8
Association Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection in South Korea.
Hypertension. 2020 Sep;76(3):742-749. doi: 10.1161/HYPERTENSIONAHA.120.15464. Epub 2020 Jul 13.
9
COVID-19: The heart of the issue.
J Card Surg. 2020 Aug;35(8):2112. doi: 10.1111/jocs.14684. Epub 2020 Jun 16.
10
Drugs and the renin-angiotensin system in covid-19.
BMJ. 2020 Apr 2;369:m1313. doi: 10.1136/bmj.m1313.
引用本文的文献
1
The Value of Common Laboratory Markers in Predicting the Severity of COVID-19 Patients.
Infect Drug Resist. 2024 Nov 13;17:5037-5047. doi: 10.2147/IDR.S478798. eCollection 2024.
2
Cardiovascular abnormalities of long-COVID syndrome: Pathogenic basis and potential strategy for treatment and rehabilitation.
Sports Med Health Sci. 2024 Mar 24;6(3):221-231. doi: 10.1016/j.smhs.2024.03.009. eCollection 2024 Sep.
3
Coronavirus Disease 2019 and Takotsubo Syndrome.
Rev Cardiovasc Med. 2022 Sep 5;23(9):298. doi: 10.31083/j.rcm2309298. eCollection 2022 Sep.
4
Nomogram to predict ventilator-associated pneumonia in large vessel occlusion stroke after endovascular treatment: a retrospective study.
Front Neurol. 2024 May 13;15:1351458. doi: 10.3389/fneur.2024.1351458. eCollection 2024.
5
A retrospective prognostic evaluation using unsupervised learning in the treatment of COVID-19 patients with hypertension treated with ACEI/ARB drugs.
PeerJ. 2024 May 13;12:e17340. doi: 10.7717/peerj.17340. eCollection 2024.
6
[Renin-Angiotensin-Aldosterone System Inhibitors should not be suspended due to SARS-CoV-2 Infection].
Arch Peru Cardiol Cir Cardiovasc. 2020 Jun 29;1(2):64-66. doi: 10.47487/apcyccv.v1i2.62. eCollection 2020 Apr-Jun.
7
Atypical Complications during the Course of COVID-19: A Comprehensive Review.
Medicina (Kaunas). 2024 Jan 15;60(1):164. doi: 10.3390/medicina60010164.
8
Coronavirus disease 2019 and cardiovascular disease.
Tzu Chi Med J. 2023 Jun 13;35(3):213-220. doi: 10.4103/tcmj.tcmj_219_22. eCollection 2023 Jul-Sep.
9
Acute and Post-Acute COVID-19 Cardiovascular Complications: A Comprehensive Review.
Cardiovasc Drugs Ther. 2024 Oct;38(5):1017-1032. doi: 10.1007/s10557-023-07465-w. Epub 2023 May 20.
10
Angiotensin-Converting Enzyme 2 Expression and Severity of SARS-CoV-2 Infection.
Microorganisms. 2023 Feb 28;11(3):612. doi: 10.3390/microorganisms11030612.
本文引用的文献
1
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
2
COVID-19 and the cardiovascular system.
Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5.
3
Clinical Characteristics of Coronavirus Disease 2019 in China.
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
4
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.
Lancet. 2020 Feb 22;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30.
5
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
6
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury.
Nat Med. 2005 Aug;11(8):875-9. doi: 10.1038/nm1267. Epub 2005 Jul 10.
7
Angiotensin-converting enzyme 2 protects from severe acute lung failure.
Nature. 2005 Jul 7;436(7047):112-6. doi: 10.1038/nature03712.
8
Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.
Circulation. 2005 May 24;111(20):2605-10. doi: 10.1161/CIRCULATIONAHA.104.510461. Epub 2005 May 16.
Zotero 插件